Nektar Therapeutics Initiates First Two Global Registrational Trials, ZENITH AD-1 and ZENITH AD-2, In Its Phase 3 Program For Rezpegaldesleukin; Initial Phase 3 Topline Data Expected In Mid-2028 With BLA Submission Targeted For 2029
Two global registrational Phase 3 trials initiated in ZENITH AD programPhase 3 program based upon clinically meaningful efficacy and favorable safety data observed in 393-patient Phase 2b study with monthly and
Nektar is moving forward with two big tests of a new medicine for a skin disease, with results expected in mid-2028. This shows the company believes the medicine works, but it's still early—results could go either way.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.